Syros Pharmaceuticals, Inc. - SYRS STOCK NEWS

Syros Pharmaceuticals (NASDAQ:SYRS) has initiated the randomized portion of its SELECT-AML-1 trial, with initial results expected in Q4 2023. The company received FDA Fast Track designation for tamibarotene in treating higher-risk myelodysplastic syndrome (HR-MDS). Enrollment for the SELECT-MDS-1 trial is on track for completion in Q4 2023, with pivotal data anticipated in Q3 2024. Financially, Syros reported a net loss of $4.8 million for Q4 2022, compared to a loss of $23.8 million in Q4 2021. The company maintains a robust cash position of $202.3 million, expected to fund operations through mid-2025.

Syros Pharmaceuticals (NASDAQ:SYRS) announces CEO Nancy Simonian, M.D., will participate in two investor conferences in March. The first is the Cowen 43rd Annual Health Care Conference on March 7 at 9:10 a.m. ET in Boston, focusing on Novel Oncology Targets. The second event is the Oppenheimer 32nd Annual Healthcare Conference on March 13 at 8:00 a.m. ET, conducted virtually. Syros is advancing treatments for hematologic malignancies through its clinical programs, including tamibarotene and SY-2101. For more details, visit www.syros.com.

Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on March 2, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year 2022 financial results. The call can be accessed by dialing (888) 575-5167 for domestic callers or (416) 764-8687 for international callers, using conference ID 74534085. Syros focuses on advancing treatment standards for hematologic malignancies. Its clinical pipeline includes tamibarotene for higher-risk myelodysplastic syndrome and acute myeloid leukemia, and SY-2101, an oral arsenic trioxide formulation for acute promyelocytic leukemia. More details are available on their website.

Syros Pharmaceuticals (NASDAQ:SYRS) granted 12,400 restricted stock units (RSUs) to two new employees as part of their employment inducement. The RSUs will vest quarterly, starting January 31, 2024, and are part of Syros’ 2022 Inducement Stock Incentive Plan. This strategic move aligns with Nasdaq Listing Rule 5635(c)(4). Syros is focused on developing cutting-edge treatments for hematologic malignancies, featuring a late-stage pipeline that includes drugs like tamibarotene and SY-2101, addressing significant medical needs in blood disorders. For further information, visit www.syros.com.

Syros Pharmaceuticals has received Fast Track Designation from the FDA for its drug tamibarotene, aimed at treating higher-risk myelodysplastic syndrome (HR-MDS) with the RARA gene overexpression. This designation highlights the serious unmet medical need for HR-MDS patients, who have a poor prognosis and limited treatment options since 2006. The pivotal SELECT-MDS-1 Phase 3 trial is currently underway, involving 190 patients across 12 countries, with enrollment expected to finish by Q4 2023 and data anticipated in Q3 2024. The company is also exploring tamibarotene's use in combination with other treatments for AML patients.

Syros Pharmaceuticals (NASDAQ:SYRS) announced key updates on its clinical trials and financial position. The company expects to complete enrollment in the SELECT-MDS-1 Phase 3 trial by Q4 2023, with data anticipated by Q3 2024. The SELECT-AML-1 Phase 2 trial is set to initiate its randomized portion in Q1 2023, with initial data expected in Q4 2023. Syros reported strong financial health, with cash sufficient to fund operations into Q2 2025, supporting its strategic focus on developing new treatment standards for hematologic malignancies.

Syros Pharmaceuticals (NASDAQ:SYRS) has granted restricted stock unit (RSU) awards totaling 14,200 shares to four newly hired employees as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs were awarded on December 22, 2022, and will vest quarterly over four years starting December 31, 2023, contingent on continued employment. Syros focuses on developing gene expression-controlling medicines, with a clinical pipeline including candidates for myelodysplastic syndrome, acute promyelocytic leukemia, and solid tumors.

Syros Pharmaceuticals announced promising results from a Phase 2 trial of tamibarotene combined with azacitidine for treating newly diagnosed, unfit acute myeloid leukemia (AML) patients with RARA overexpression. The trial showed a high complete response (CR) rate of 50% and an overall response rate (ORR) of 67% among those with RARA overexpression. The treatment was generally well tolerated, with no significant added toxicity. Syros is advancing to Phase 3 and Phase 2 trials to further evaluate tamibarotene in myelodysplastic syndrome (MDS) and AML.

Syros Pharmaceuticals (NASDAQ:SYRS) announced promising results from the SELECT-AML-1 Phase 2 trial of tamibarotene for acute myeloid leukemia (AML) patients with RARA gene overexpression. The triplet regimen achieved an 83% composite complete response rate among evaluable patients, significantly surpassing the standard CR rate of 66%. Initial data revealed no increased safety concerns compared to existing treatments. Syros plans to advance to the randomized trial phase in Q1 2023, with results expected in 2023 or 2024.